Return to search results.
Complete title: A Multicenter, Randomized, Controlled, Two-Arm, Phase III Study to Evaluate the Safety and Efficacy of MK-3475 Compared to Ipilimumab in Patients with Advanced Melanoma
|Research Study Number||20130483|
|Principal Investigator||Kim Margolin, MD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Melanoma; Skin Cancer; Solid Tumors; Neuroendocrine Tumor
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.